Showing 1 posts of 1 posts found.
ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement